Screener
Iovance Biotherapeutics, Inc. IOVA Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Iovance Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 9:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091716
FAQ
- What is Iovance Biotherapeutics, Inc.'s total equity?
- Iovance Biotherapeutics, Inc. (IOVA) reported total equity of $736.05M in Q2 2026.
- How has Iovance Biotherapeutics, Inc.'s total equity changed year-over-year?
- Iovance Biotherapeutics, Inc.'s total equity increased by 5.4% year-over-year, from $698.49M to $736.05M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s total equity?
- Over 5 years (2020 to 2025), Iovance Biotherapeutics, Inc.'s total equity has grown at a 1.3% compound annual growth rate (CAGR), from $656.5M to $698.58M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Iovance Biotherapeutics, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude